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Abstract
Mammalian genomes encode at least 15 distinct DNA polymerases, functioning as specialists in
DNA replication, DNA repair, recombination, or bypass of DNA damage. Although the DNA pol
zeta(ζ) catalytic subunit REV3L is important in defense against genotoxins, little is known of its
biological function. This is because REV3L is essential during embryogenesis, unlike other
translesion DNA polymerases. Outstanding questions include whether any adult cells are viable in
the absence of Polζ, and whether Polζ status influences tumorigenesis. REV3L-deficient cells have
properties that could influence the development of neoplasia in opposing ways: markedly reduced
damage- induced point mutagenesis, and extensive chromosome instability. To answer these
questions, Rev3L was conditionally deleted from tissues of adult mice using MMTV-Cre. Loss of
REV3L was tolerated in epithelial tissues, but not in the hematopoietic lineage. Thymic
lymphomas in Tp53−/− Rev3L conditional mice occurred with decreased latency and higher
incidence. The lymphomas were populated predominantly by Rev3L null T-cells, demonstrating
that loss of Rev3L can promote tumorigenesis. Remarkably, the tumors were frequently
oligoclonal, consistent with accelerated genetic changes in the absence of Rev3L. Mammary
tumors could also arise from Rev3L-deleted cells, in both Tp53+/+ and Tp53+/− backgrounds.
Mammary tumors in Tp53+/− mice deleting Rev3L formed months earlier than mammary tumors
in Tp53+/− control mice. Prominent preneoplastic changes in glandular tissue adjacent to these
tumors occurred only in mice deleting Rev3L and were associated with increased tumor
multiplicity. Polζ is the only specialized DNA polymerase yet identified that inhibits spontaneous
tumor development.
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Introduction
Despite the cell’s many DNA repair mechanisms, genomic replication and cell division
frequently take place with unrepaired DNA lesions still present. Bypass of such lesions can
be performed by enzymes known as translesion synthesis DNA polymerases, which have
activities on differing substrates (1,2). Included in this group of enzymes in mammals are
polζ, polη, polι, polκ, polθ, polν, and Rev1 (1,2). The best characterized is pol η, which
inserts bases across from UV radiation-induced cyclobutane pyrimidine dimers in DNA. A
deficiency of the human enzyme causes the hereditary skin cancer- prone disorder
xeroderma pigmentosum variant (XP-V) (1).
Polζ has been difficult to study because unlike other specialized DNA polymerases, its
catalytic subunit REV3L is essential for development. This indicates that polζ has a non-
redundant function, perhaps bypass of endogenous DNA damage in the rapidly growing
embryo (3–6). The mammalian REV3L gene (7,8) encodes a polypeptide of ~350 kDa, twice
as large as the catalytic subunit of yeast polζ, Rev3. Reduced REV3L function in human and
mouse fibroblasts decreases base change mutagenesis induced by UV light and other
mutagens (9–11). REV3L therefore differs markedly from the other DNA polymerases,
because interfering with its function reduces rather than increases point mutagenesis.
Polζ-defective cell lines have only been isolated in p53-compromised backgrounds. Rev3L
null mouse embryonic fibroblasts exhibit spontaneous chromosomal instability, with an
increase of ~10-fold in the frequency of chromosome translocations (12); other Rev3L null
cells also have increased frequencies of chromosome breaks and translocations (13–16).
This is consistent with a role for DNA polζ in bypass of adducts that would otherwise block
DNA replication and lead to replication fork collapse and breakage. Alternatively, REV3L
might function in the repair synthesis that occurs during some forms of DNA double strand
break repair (16–19). We undertook a study to answer two basic questions. The first is if
Rev3L loss can be tolerated in normal adult cells. A second is whether the loss of REV3L in
adult cells affects the development of spontaneous neoplasia.
Materials and Methods
Conditional Rev3L allele targeting construct
The conditional targeting construct (Fig. 1A) was based on that used to replace two exons
containing the 3′ end of motif I and all of motif V within the REV3L polymerase domain
active site (5). The plasmid backbone (pBluescript II KS+) and the Rev3L genomic
homology arms were retained and loxP sites were added at the internal edges of the
homology arms. At the 3′ end of the 5′ homology arm (BspE1 site), a neomycin resistance
gene surrounded by loxP sites was added. This cassette was excised from plasmid pL2-neo
(created by Hua Gu), contained a 1.1 kb linker regions and is expressed by the HSV tk
promoter. A loxP site formed by annealing oligonucleotides was ligated to the 5′ end of the
3′ homology arm (SalI site). Finally the 4.6 kb of genomic sequence missing between the
homology arm sequences and containing the essential polymerase exons was amplified from
129/Ola genomic DNA using Expand High Fidelity polymerase (Roche). This PCR product
was cloned between the 5′ neo cassette flanked by loxP sites and the single 3′ loxP site. The
final targeting construct contained 3 loxP sites and 4 exons (2 within the original 3′
homology arm and the 2 essential pol exons now flanked by loxP sites). The sequence of the
exons and loxP sites was confirmed by DNA sequencing. It is not currently known whether
any truncated REV3L protein is produced by this conditional construct.
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Targeted ES cell identification
The 3loxP targeting construct was linearized and electroporated into 129/Ola ES cells. Two
ES cell clones were found to be correctly targeted (both 5′ and 3′ arms recombined) by
nested PCR using decreasing temperature annealing steps. Southern blotting was performed
to confirm this and to ensure that a second non-homologous integration had not occurred.
The neo selection cassette flanked by loxP sites was removed by transient expression of a
Cre recombinase plasmid within the ES cells. Individual colonies were then replica plated
with one plate grown in the presence of G418 to identify those cells likely to have deleted
the neo cassette. PCR screening was then employed to distinguish between colonies that had
deleted the neo cassette only (to create the lox construct) versus those that also deleted the
Rev3L exons because the outermost loxP sites had been utilized by Cre (creating a null
allele). Southern blotting confirmed results and eliminated mixed ES cell colonies.
Mouse strains and breeding
Two ES cell clones with the two essential DNA polymerase exons flanked by loxP sites
were injected into C57BL6/J blastocysts. One clone generated pups with a transgenic
germline. The Rev3L and Tp53 (20) strains were mixed B6;129. Mouse strains Tg(MMTV-
Cre)1mam and Tg(MMTV-Cre)4mam, originally obtained from the Jackson laboratory on a
FVB background, were bred to the Rev3L+/− strain (5). Mice were maintained as outbred by
non-sibling matings. All experimental crosses were Rev3Llox/lox to Rev3L+/− MMTV-Cre,
including those examining the effects of a Tp53 null background. Details of animal
monitoring, necropsy and histology are in Supplementary Information.
Rev3L conditional allele deletion assay
A PCR assay was developed to determine the relative levels of conditional allele deletion in
tissues and tumors of Rev3L+/lox Cre and Rev3L−/lox Cre mice. Genomic DNA was prepared
from tissues and tumors using DNeasy columns (Qiagen). Keratinocyte culture and bone
marrow lineage separation methods are in Supplementary Information. Triplex PCR used a
forward primer common to both the lox and Δlox alleles and reverse primers unique to each
allele. PCR reaction mixtures (25 μl) contained 200 μM each dNTP, 0.6 μM common
primer, 0.3 μM of each allele-specific primer, 25–100 ng genomic DNA, and 0.13 μl Qiagen
HotStar TaqPol (0.63 units). The annealing temperature (57 °C) was optimized to reflect
defined input ratios of lox and Δlox genomic DNAs obtained from pure ES cell clones. After
30 cycles PCR, the 647 bp (lox) and 511 bp (Δlox) PCR products were separated on a 1.2%
agarose gel.
Clonality analysis of thymic tumors
Genomic DNA from thymic lymphomas was analyzed to survey DJ rearrangements within
Tcrb, essentially as described (21,22). Details are in Supplementary Information.
Results
Polζ deletion is tolerated in epithelial but not hematopoietic tissues
Because of the embryonic lethality of Rev3L deletion, we developed a conditional knock-out
mouse to determine the consequence of Polζ deletion for viability of different adult cell
types and spontaneous tumorigenesis. Two essential exons in the DNA polymerase domain
of the Rev3L gene were flanked by loxP sites so that they could be deleted by Cre
recombinase (Fig. 1A). No differences in phenotype were apparent among Rev3L+/+,
Rev3L+/−, Rev3L+/lox and Rev3L−/lox mice. To conditionally inactivate Rev3L, the lines
Tg(MMTV-Cre)1mam and Tg(MMTV-Cre)4mam were used in crosses (23). In adults, both
show highest levels of Cre expression in secretory tissues, the hematopoietic system
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(including B and T cells, megakaryocytes, and the erythroid lineage), and epithelia. Some
MMTV-Cre expression may occur in embryos after 11.5 days of development (23). The life
spans and weights of adult mice deleting the conditional lox allele to generate either Rev3L
heterozygous (+ /Δlox) or Rev3L null (−/Δlox) cells were not statistically different from
non-Cre controls (Fig. S1A).
A PCR assay was developed to quantify deletion in genomic DNA from Cre-expressing
tissues (Fig. 1B). Significantly, deletion of Rev3L to null status was tolerated in epithelial
tissues, including samples from the tail, ear and salivary gland, though probably with some
loss of viability (Fig. 1B). Rev3L null cells were still present in these tissues in two year old
Rev3L−/loxCre mice. We confirmed that Rev3L null keratinocytes are viable and can divide
ex vivo (Fig. S2A).
The consequence of Rev3L deletion was quite different in hematopoietic tissues. In
Rev3L−/loxCre mice, the deleted form of the conditional Rev3L allele was not detected or
was present in only trace amounts in bone marrow, spleen, thymus and lymph nodes (Fig.
1C). The conditional Rev3L allele was consistently disrupted at a level of ~50% in the
hematopoeitic tissues of all Rev3L+/loxCre control mice tested (Fig. 1C). Poor viability of
Rev3L-deleted lymphoid cells was not a consequence of the introduction of double-strand
breaks mediated by V(D)J recombination during the maturation of lymphocytes (Fig. S2B).
This demonstrates an essential requirement for pol ζ in maintaining viability in adult
hematopoietic lineages.
Formation of Rev3L-null lymphoma
A lack of Rev3L could accelerate the formation of oncogenic rearrangements or inactivation
of tumor suppressors. Lymphomas were the most common tumor in Tp53+/+ Rev3L−/loxCre
mice and occurred with frequencies similar to the control genotypes. Most did not contain
Rev3L null cells (Fig. S3A). Nevertheless, among the hematopoietic masses examined from
8 Rev3L−/loxCre mice, one T-lymphoblastic lymphoma/leukemia occurred very early (3.5
months) and was dominated by Rev3L null cells (Fig. 2A, S3B). Thus complete loss of
Rev3L was an early event in this tumor and the final change(s) required for uncontrolled
growth occurred in a cell lacking Rev3L function.
Loss of Rev3L enhances incidence and accelerates the development of lymphoma
Mice were placed in a Tp53-null background, where the influence of Rev3L disruption on
the frequency and latency of spotaneous thymic lymphoma could be measured. Cellular
lethality upon Rev3L deletion is partially due to p53-imposed controls (12,14,15,24).
Deletion of Tp53 did not globally allow blood cells to proliferate without Rev3L function, as
there was near or total absence of cells with complete disruption in the bone marrow, spleen
and mesenteric lymph node of Rev3L−/loxTp53−/−Cre mice (Figs. S4A and B). However,
examination of Rev3L deletion in the thymus of two Rev3L−/loxTp53−/−Cre4mam mice
without obvious lymphoma revealed that absence of Tp53 did promote the ability of Rev3L
null thymocytes to divide in vivo (Fig. S4A and B). In one case (Fig. S4B), Rev3L deleted
cells were found only in a single thymic lobe, suggesting that absence of Tp53 is necessary
but not sufficient for bypass of the genomic defect(s) induced by Rev3L loss.
Twenty-one of the 22 mice in the Rev3L−/loxTp53−/−Cre group succumbed to thymic
lymphoma by 142 days (Table 1). The one that did not was euthanized at six weeks due to
exencephaly known to occur in Tp53 null mice (25). The incidence of thymic lymphomas in
the Rev3L−/loxTp53−/−Cre1mam group was thus 100%, revealing complete penetrance in
mice capable of forming Rev3L null lymphocytes. This is significantly greater than the 70 –
77% frequency in control genotypes (p<0.03, Table 1), a frequency consistent with other
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studies of Tp53−/− mice (20,26). Eleven tumors from Rev3L−/lox Tp53−/−Cre1mam mice
were examined histologically and all were precursor T-lymphoblastic leukemia/lymphomas,
based on CD3+TdT+ immunostaining and morphology. This is the predominant form of
lymphoma arising in Tp53 null mice (27).
Mice from the Rev3L−/loxTp53−/−Cre group forming Rev3L null lymphomas have
significantly decreased survival compared to the three control genotypes retaining at least
one functional Rev3L allele (Fig. 3; p<0.0002, Table 1). Similar differences between the
deleting and non-deleting genotypes were found by comparing only the survival of mice
with lymphoma (Table 1). Genotyping multiple samples from 14 of the lymphomas from the
Rev3L−/loxTp53−/−Cre1mam group showed that 10 were predominantly constituted by
Rev3L null cells (representative results, Fig. 2B). One lymphoma had a mixed population
that was mostly Rev3L null, but had one thymus sample also containing parental, non-
deleted Rev3L cells (Fig. 2C). Three lymphomas contained only cells with the intact
conditional allele. Thus, loss of Rev3L enhances development of thymic lymphoma in Tp53
null mice both by increasing incidence and by shortening the latency of tumors.
Rev3L null tumors are frequently oligoclonal
To test whether Rev3L− cells have an increased probability of neoplastic conversion, we
asked whether thymic lymphomas arising from them are multiclonal. T-cell lymphomas
from Tp53 null mice have clonal Tcrb rearrangements (28). Clonality in thymic lymphomas
was assessed by determining the number, distribution and sizes of D-J rearrangements
within the Tcrb (TCR-β) gene (22) in 10 Rev3L+ and 10 Rev3L− thymic lymphomas. To
assess whether cell populations differed across the tumor, multiple genomic DNA samples
from non-adjacent sites of each tumor were assayed simultaneously. D1-J1, D2-J2 and D1-
J2 joined segments were amplified in separate PCR reactions (Fig. 4A) that paired Rev3L−
tumors with Rev3L+ tumors (Fig. 4B, C, D). Non-tumor thymus DNA from a Tp53 null
mouse served as a control to identify the sizes of normal rearrangements, all of which can be
found in a normal thymus, including those involving a J2 pseudosegment (Fig. 4C, D, right).
From the ten Rev3L+ tumors, 48 total independent samples were analyzed; only one instance
was found with different clonal proliferations at different locations within the tumor (Fig.
4B). Analysis of 39 samples from different sites of the ten Rev3L− tumors revealed that five
Rev3L− tumors had different clonal populations in separate samples from the same tumor
(Fig. 4B, C, D).
D-J recombination can occur on both alleles of the Tcrb locus (29). To classify a tumor
sample as biclonal based on number of rearrangements, more than two J1 or J2
rearrangements must be present in an individual sample. No Rev3L+ tumor samples had so
many products, whereas three Rev3L− tumors had more than two D2-J2 rearrangements in
an individual sample. One of these was not among the five having different clonal
populations at non-adjacent sites within the same tumor. The analyses together identify a
significantly increased number of Rev3L null tumors that are at least biclonal (Fig. 4B).
The Rev3L− lymphoma group also had five D-J rearrangement products with sizes distinctly
different than the standard rearrangements (Fig. 4B, C, D); only one such rearrangement
occurred in the Rev3L+ group (Fig. 4B). The occurrence of aberrantly migrating D-J
rearrangements suggests that processing of VDJ intermediates might be altered in Rev3L
null T-cells. Rev3L may also be involved in the repair of strand breaks occurring during
class switch recombination (16).
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Loss of Rev3L in mammary tumors
Mammary tumors were also observed in Rev3L-deleting females in the Tp53+/+ cohort
(Table S2). Notably, 5 of the 6 mammary tumors in Rev3L−/loxCre females were composed
largely of Rev3L null cells (Fig. S5A). The single mammary tumor (a solid carcinoma) from
the Rev3L+/loxCre genotype had no Rev3L deletion (Fig. S5B).
To further examine the effect of Rev3L deletion on tumor incidence and latency, we
generated cohorts of Rev3L-deleting and control genotypes in a Tp53-sensitized background.
On the Tp53+/− background, significantly more mammary tumors occurred in mice deleting
Rev3L than those retaining Rev3L function (Table S3, p=0.044). Eighteen mammary tumors
were found in 11 Rev3L−/loxTp53+/−Cre1mam mice, with 4 of these in males. The numbers
of females with mammary tumors from the Tp53+/− and Tp53+/+ cohorts were combined for
each Rev3L genotype (although tumor numbers were smaller in the Tp53+/+ cohort). The
number of Rev3L-deleting females that developed mammary tumors was significantly
greater than the combined Rev3L+/loxCre control group, which had the next highest
incidence (14 vs. 5 females, 41 total females in each group, p=0.035, Fisher’s exact test).
Four Rev3L−/loxTp53+/−Cre1mam mice but only a single control mouse developed multiple
mammary tumors. As in the Tp53+/+ cohort, most mammary tumors (12/17 analyzed) in
Rev3L-deleting mice were comprised largely of Rev3L null cells; samples from 2 other
tumors contained 25–50% deletion. The increased number of mammary tumors populated
by Rev3L null cells in Rev3L-deleting females strongly suggests that loss of REV3L
promotes mammary tumorigenesis.
Mammary tumors in Rev3L deleting mice had a shorter latency than in control genotypes in
the Tp53+/− background (median 295 vs. 448 days, p=0.02, log-rank). Loss of Rev3L thus
reduced tumor latency in addition to increasing tumor incidence. Survival of
Rev3L−/loxTp53+/−Cre1mam mice as a group was not significantly different from controls
(Fig. S1B). Similar numbers of lymphomas developed in all 4 Tp53+/− genotypes (22–34%),
comparable to previously reported incidences (26).
Increased formation of mammary preneoplastic lesions in mice deleting Rev3L
Mice on the Tp53+/− background, regardless of Rev3L status, developed a similar spectrum
of mammary tumors, including carcinosarcomas, adenosquamous carcinomas, solid
carcinomas, and sarcomas (Table S3). Half of the mammary tumors in
Rev3L−/loxTp53+/−Cre1mam mice were solid carcinomas (compared to 1 of 7 mammary
tumors in the 3 control genotypes); these tumors generally had the highest proportion of
Rev3L null cells among the mammary tumors from Rev3L deleting mice.
Glandular tissue adjacent to the mammary tumors from Rev3L-deleting mice often had
mammary intraepithelial neoplasia (MIN) and marked atypical hyperplasia (Fig. 5A). In
these mice, MIN was observed adjacent to at least 7 tumors of different types. The 6 control
genotype tumors with adjacent glandular tissue had no MIN and only the single control
mouse with multiple mammary tumors had mild to moderate hyperplasia (Fig. 5A). In the
Tp53+/+ cohort, MIN was found adjacent only to one Rev3L null adenosquamous carcinoma
(Rev3L−/loxCre1mam female). Atypical hyperplasia and MIN would clearly predispose
Rev3L-deleting mice to the development of multiple mammary tumors. Moreover, some
mammary tumors in Rev3L-deleting mice may have been formed by the confluence of
multiple neoplastic foci, as 3 of the 4 Rev3L−/lox Tp53+/−Cre1mam mice with multiple
tumors (Fig. 5B) also had multiple MIN adjacent to the tumors. Thus loss of Rev3L in a
Tp53+/− background causes an increase in the number of both preneoplastic and neoplastic
lesions.
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Discussion
The conditional Rev3L knockout mouse permitted a test of the viability of tissues lacking
polζ function. Epithelial cells from the tail, ear and salivary gland tolerated deletion of
Rev3L, and null keratinocytes underwent at least 3–4 cell divisions in culture. In contrast,
Rev3L null hematopoietic cells did not proliferate, consistent with the severe early
hematopoiesis defect previously found in Rev3L null embryos (6). Hematopoietic tissues
may be especially dependent on Rev3L for their survival, due to high basal levels of p53
(30), a higher load of reactive oxygen species (31), or a greater dependence on polζ-
dependent DNA replication and repair. Removal of p53 did not enable viability of all blood
cells, but promoted survival of Rev3L null thymocytes. This suggests that a Tp53-
independent response is present, but that it can be bypassed or inactivated. Both Tp53-
dependent and Tp53-independent pathways exist to induce cell cycle arrest, senescence,
stasis, and apoptosis (32–34).
Remarkably, REV3L-negative tumors grew aggressively, although Rev3L is essential for
embryonic development and viability of MEFs and blood cells. In Tp53−/− mice, deleting
the conditional Rev3L allele reduced lifespan and increased thymic lymphoma incidence to
100%. Most lymphomas consisted primarily of Rev3L null cells, indicating that REV3L loss
accelerates lymphoma development. Loss of Rev3L reduced mammary tumor latency in
Tp53+/− mice, increased tumor multiplicity, and promoted the occurrence of mammary
tumors in males. For both T-cell and mammary tumorigenesis, Rev3L loss apparently
increases the number of cells at risk for neoplastic conversion. More Rev3L− tumors were
oligoclonal, and mammary intraepithelial neoplasia was a distinct feature of adjacent
glandular tissue in Rev3L null mammary tumors.
Genomic instability due to Rev3L loss has been previously documented in chicken, mouse
and human cells, with increased formation of DNA breaks and translocations (12–16). This
provides a likely explanation for enhanced tumorigenesis in Tp53-deficient mice deleting
Rev3L. Increased genetic instability is known to accelerate tumorigenesis, although the
generation of DNA breaks may require that Tp53-mediated controls be removed or
attenuated.
The precise cellular function of REV3L in limiting genome instability remains to be
determined. One possibility is that DNA polζ has a role in bypass of some endogenously
formed adducts that would otherwise block DNA replication and lead to replication fork
collapse and breakage. Alternatively, REV3L might function in the repair synthesis that
occurs during DNA double strand break repair. The mid-gestation lethality of Rev3L
deletion and severe proliferation defect of null embryonic fibroblasts somewhat resembles
knockouts of genes involved in homologous recombination (HR), such as Rad51, Rad51d,
Xrcc2, and Brca (3). Rev3L and HR null knockouts also share features of chromosome
instability and Tp53 absence enables cells lacking these genome maintenance genes to
overcome blocked cell division (35). Deletion of Brca1 or Brca2 in Tp53+/+ mice by
MMTV-Cre results in mammary tumors with average latencies similar to that caused by
Rev3L deletion (36,37). Tp53 heterozygosity cooperates with the loss of all 3 of these genes
to reduce the average latency of mammary tumor formation to between 8.5 months (Brca1)
and 10.5 months (Rev3L). Deletion of Rev3L by MMTV-Cre in Tp53+/− mice induced
multiple mammary tumors, as it did for the (more penetrant) Brca1 (36). Deletion of the
Brca alleles in Tp53−/− mice using the T-cell lineage specific Lck-Cre (38,39) has effects on
incidence and latency of thymic lymphoma similar to the acceleration of T-cell lymphoma
caused by Rev3L deletion.
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The present results with Rev3L identify a specialized DNA polymerase that uniquely inhibits
spontaneous tumor development in mammals The finding that epithelial cells can survive in
the absence of pol zeta opens the way to further investigations of the specific roles of this
enzyme in epithelial neoplasia, including UV-induced skin cancer.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Conditional inactivation of Rev3L
A. Rev3L cDNA encodes a 3122 amino acid protein, with conserved DNA polymerase
motifs (I - VI) and a zinc finger (ZF) motif near the C-terminus. (i). A segment of Rev3L
genomic DNA (+ allele) with exons (vertical bars). The two exons in red contain part of
motif I and all of V. (ii). These two conserved exons encoding amino acids 2776–2860 were
replaced by a lacZ-neor cassette to disrupt the gene (− allele) as described (5). (iii). For the
functional “floxed allele” two LoxP sites (black triangles) are incorporated into introns
flanking these exons. (iv). Cre recombinase deletes these exons and intervening sequence to
give the Δlox allele. The lox allele is detected with PCR primers C1 and F1 (arrows) and the
Δlox allele with PCR primers C1 and D1.
B. Epithelial cells tolerate deletion of Rev3L. Genomic DNA samples (35 ng) from tail, ear,
and salivary gland of Rev3L conditional knockout mice contain Rev3L null cells (−/Δlox) as
well as cells with an intact allele (lox). For each genotype, DNA was analyzed from tissues
of three different mice possessing the MMTV-Cre4mam transgene at 7 months (tail), 13–16
months (ear) and 16 months (salivary gland). The right side of the top panel shows a control
PCR titration with the indicated ratios of lox and Δlox genomic DNA (35 ng total per lane).
Lanes with a 1:1 mixture of lox and Δlox DNA are indicated by C.
C. Adult hematopoietic tissues do not normally tolerate Rev3L deletion. Samples (35 ng
genomic DNA) from spleen, thymus, lymph node, and bone marrow of Rev3L conditional
knockout mice do not contain detectable Rev3L null cells (−/Δlox). If one wild-type allele of
Rev3L is present, deletion produces Rev3L+/ Δlox cells. The tissues shown at bottom are from
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single 14 month old mice of each genotype, both possessing the MMTV-Cre4mam
transgene.
Wittschieben et al. Page 12
Cancer Res. Author manuscript; available in PMC 2011 April 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 2. Rev3L null T-cells can form tumors in mice
A. Samples of tumor tissue, spleen and bone marrow from a 3.5 month-old Rev3L−/lox
Tp53+/+ Cre1mam mouse show major populations of Rev3L null cells, identified as
precursor T-lymphoblastic leukemia/ lymphoma (Fig. S3B). Control sample (C) is a 1:1
mixture of lox and Δlox DNA.
B. Thymic lymphomas in Rev3L−/lox Tp53−/− Cre1mam mice are usually populated by
Rev3L null cells. Tissues from three different mice are displayed. All animals were dead or
moribund at three months of age. Multiple samples from thymus show that Rev3L null cells
dominate the thymic tumor in all three mice. Abbreviations: mesenteric lymph node “mes
l.n.”, salivary gland, “sal. gl.”, mammary gland “mamm.”.
C. Rev3L null cells dominated two lobes of this thymic lymphoma from a Rev3L−/lox
Tp53−/− Cre1mam mouse, while another lobe showed a mixed population. Control samples
(C) as in part A, other abbreviations as in part B.
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Figure 3. Accelerated tumorigenesis in Tp53-null mice deleting Rev3L
Kaplan-Meier plot of mouse survival with time. Sample sizes, mean and median values in
Table 1. The difference in survival of Rev3L−/lox Tp53−/− Cre1mam to the other 3 genotypes
was highly significant by two-sided log-rank analysis: Rev3L+/lox Tp53−/− Cre (P<0.0001),
Rev3L−/lox Tp53−/− (p=0.0002) and Rev3L+/lox Tp53−/− (p<0.0001). Rev3L−/lox Tp53−/−
Cre1mam solid black; Rev3L+/lox Tp53−/− Cre1mam dotted green; Rev3L−/loxTp53−/− dotted
blue; Rev3L+/lox Tp53−/− dotted magenta.
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Figure 4. Increased oligoclonality within Rev3L null tumors
A. Schematic of D-J segments within the Tcrb gene. Locations of primers are indicated by
arrowheads. J2.6 is a pseudosegment in the mouse, not yielding productive rearangements.
Segment D2 rearrangement is possible with any one of 6 different J2 gene coding segments.
The D1 segment generally joins with 6 J1 coding segments and to a lesser extent, the 6 J2
segments.
B. D–J rearrangements of the Tcrb gene in murine Tp53−/− thymic lymphomas. “g.l” is
germline. Darker shaded rows indicate tumors that were at least biclonal. The increased
number of biclonal tumors in the Rev3L− group relative to the Rev3L+ group (6 versus 1) is
statistically significant (Fisher’s exact test, one-tailed, p=0.03).
1 “-”, no rearrangement of this type was detected. 2 verified by independent PCR. * product
found in only one sample from a tumor, and verified by independent PCR. † product found
in two or more, but not all samples from a tumor
C. Non-adjacent samples of lymphomas from Rev3L− and Rev3L+ samples were surveyed
for D2-J2 rearrangements. In this example, two Rev3L− lymphoma samples show distinct
populations of Tcrb rearrangements and one sample contains both populations. The arrow
shows an aberrant product not corresponding to the set of normal outcomes of
recombination in 2 samples. The full distribution of rearrangements is found in the non-
tumor thymus sample at the right.
D. Non-adjacent samples of a Rev3L− and a Rev3L+ lymphoma were surveyed for D2-J2 and
D1-J2 rearrangements. More than one clone of rearranged cells is present within the Rev3L−
tumor. The arrow shows an aberrant event, as D1-J2 PCR will not amplify a product of
germline size. A product with this size would arise if a rare D1 to D2 joining event had
occurred. The Rev3L+ lymphoma is monoclonal, harboring a D2-J2.7 rearrangement in the
four tumor samples.
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Figure 5. Neoplasia and preneoplasia in Tp53+/− mice deleting Rev3L
A. Multifocal atypical hyperplasia and mammary intraepithelial neoplasia (MIN),
characterized by increased cellularity, cellular atypia, and filling of alveoli with solid,
papillary, or multilayered proliferations of epithelium, were seen only in mice deleting
Rev3L, although mammary tumor morphology was similar for both Rev3L- and Rev 3L+
tumors in Tp53+/− mice. Atypical hyperplasia and MIN was seen in 5 of the 9 Rev3L−/lox
Tp53+/−Cre1mam mice for which glandular tissue adjacent to tumors could be examined.
All tissues shown at the same magnification. (Scale bar: 100 μm).
B. Multiple adjacent preneoplastic and hyperplastic mammary nodules were observed in
Tp53+/− mice deleting Rev3L, as shown in this panel, but not in mice that retained Rev3L.
(Scale bar: 1 mm).
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